Hospital
Luminis Health Anne Arundel Medical Center, INC.
Luminis Health Anne Arundel Medical Center, INC. was paid $2.58M by Medicaid between Jan 2018 and Dec 2024, across 75 billing codes. Its largest line is 99284, emergency room visit (serious) — 44% of everything it billed.
33Billing provider infoLUMINIS HEALTH ANNE ARUNDEL MEDICAL CENTER, INC.
ANNAPOLIS, MD 21401
ANNAPOLIS, MD 21401
33aNPI1477517225assigned 04/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.58M
24GClaims90,775
24DCodes billed75
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Maryland
Rank by total paid#18 of 69
Median peer was paid$870K
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,910 | $125K | |
| 2019 | 16,740 | $330K | |
| 2020 | 11,826 | $456K | |
| 2021 | 13,924 | $503K | |
| 2022 | 15,318 | $519K | |
| 2023 | 11,459 | $379K | |
| 2024incomplete | 6,598 | $267K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 44% | 8,924 | 7,602 | $1.15M |
| G0378 | Hospital observation service, per hour | 26% | 1,407 | 1,216 | $672K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 2,677 | 2,425 | $426K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.4% | 1,276 | 1,165 | $88K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.9% | 55 | 54 | $75K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.8% | 4,304 | 3,395 | $72K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 152 | 95 | $27K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 532 | 396 | $24K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,197 | 552 | $13K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,409 | 8,579 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,098 | 1,038 | $5K |
| 80053 | Comprehensive metabolic panel | <1% | 6,470 | 5,345 | $4K |
63 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,222 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,452 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,244 | $2K |
| 84484 | <1% | 2,879 | $2K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,303 | $1K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,411 | $1K |
| 97162 | <1% | 27 | $1K | |
| 81001 | <1% | 3,812 | $1K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 171 | $911.33 |
| 87631 | <1% | 61 | $711.74 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 101 | $573.14 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 92 | $470.14 |
| 83690 | <1% | 1,876 | $442.20 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 159 | $409.87 |
| 71045 | Radiologic examination, chest; single view | <1% | 1,216 | $397.14 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 398 | $330.57 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 642 | $303.46 |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 251 | $197.63 |
| 84703 | <1% | 230 | $188.40 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 321 | $144.32 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 1,128 | $137.30 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,296 | $135.80 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,291 | $135.08 |
| 82948 | <1% | 3,537 | $117.53 | |
| 82248 | <1% | 1,546 | $86.46 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,870 | $60.46 |
| 80076 | <1% | 128 | $45.56 | |
| 85610 | <1% | 126 | $39.79 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 423 | $35.14 |
| J3490 | Unclassified drugs | <1% | 790 | $23.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,920 | $19.05 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,523 | $14.04 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 932 | $12.82 |
| 87077 | <1% | 12 | $12.31 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 120 | $10.81 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,500 | $7.59 |
| 85014 | <1% | 20 | $4.81 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 813 | $3.52 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,747 | $3.49 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 188 | $3.43 |
| 82077 | 0% | 350 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 309 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 148 | $0.00 |
| 85027 | 0% | 45 | $0.00 | |
| 83880 | 0% | 115 | $0.00 | |
| 86901 | 0% | 27 | $0.00 | |
| 83605 | 0% | 105 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 82 | $0.00 |
| C1769 | Guide wire | 0% | 30 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 17 | $0.00 |
| 86850 | 0% | 27 | $0.00 | |
| 85379 | 0% | 15 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 143 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 122 | $0.00 |
| 80179 | 0% | 226 | $0.00 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 141 | $0.00 |
| 86900 | 0% | 27 | $0.00 | |
| 80143 | 0% | 226 | $0.00 | |
| 97164 | 0% | 12 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 168 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 136 | $0.00 |
| 81025 | 0% | 12 | $0.00 | |
| 71250 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVELLEN, JASON (DIRECTOR, PATIENT FINANCIAL SERVICE)
| Provider | Location | Paid |
|---|---|---|
| Luminis Health Doctors Community Medical Center, INC. | Lanham, MD | $9.88M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.